Compare Nerdwallet Inc (NRDS) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nerdwallet Inc vs ResMed Inc. — how do they compare? Nerdwallet Inc trades at $9.68 (market cap $625.17M), while ResMed Inc. trades at $230.12 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 51× Nerdwallet Inc's market cap, and ResMed Inc. pays a 1.16% dividend while Nerdwallet Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nerdwallet Inc for 45 Days and ResMed Inc. for 51 Days on average.
| NRDS | RMD | |
|---|---|---|
Market Cap | $625.17M | $31.89B |
Volume | 1,321,316 | 618,314 |
Sector | Media | Health |
52-Week High | $15.93 | $277.88 |
52-Week Low | $7.58 | $182.82 |
Typical Hold Time | 45 Days | 51 Days |
Enterprise Value | $539.47M | $31.24B |
Dividend Yield | — | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NerdWallet (NRDS) trades at $9.74, up 7.21% today, showing strong momentum despite a recent Q2 2026 earnings miss. The stock exhibits bullish technical signals with positive moving averages and strong institutional support. Fundamentally, the company demonstrates robust revenue growth from $539M in 2022 to $837M in 2025, with improving profitability margins. Recent news highlights the company's Financial Resilience Index publications and Wall Street's positive outlook.
The outlook remains positive with analyst consensus favoring Buy ratings (66.7%) and projecting 27.9% upside potential. Key opportunities include continued revenue growth and margin expansion, while risks involve organic search pressure in core products and macroeconomic sensitivity. The stock presents a compelling value proposition with attractive valuation multiples.
ResMed (RMD) trades at $230.05, up 1.8% on the day, with a bullish technical outlook and strong fundamental performance. The company reported consistent earnings beats in recent quarters, with Q2 2026 EPS of $2.95 exceeding the $2.89 estimate. Revenue growth is robust, reaching $5.15 billion in 2025, while profitability metrics like a 26.94% net income margin and 24.27% ROE highlight operational efficiency. Recent news includes an upcoming Q1 2027 earnings report and positive analyst commentary on growth prospects driven by demand in sleep therapy.
The investment outlook is positive, supported by earnings momentum, a consensus price target of $242.70, and institutional buying. Key risks include competitive pressures, regulatory investigations, and macroeconomic volatility. The stock offers upside potential but requires monitoring of execution and external challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Nerdwallet Inc
Nerdwallet Inc is a free tool to find you the best credit cards, cd rates, savings, checking accounts, scholarships, healthcare and airlines.
Read more on NRDS →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
